Cue Biopharma to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference

GlobeNewswireNov 12 08:00 ET

JMP Securities Maintains Cue Biopharma(CUE.US) With Buy Rating, Maintains Target Price $2

Moomoo NewsNov 11 00:33 ET · Ratings

Cue Biopharma: Strategic Shift and Promising Clinical Results Support Buy Recommendation

TipRanksNov 11 00:25 ET

Cue Biopharma Presents 'Positive' Update From Phase 1 Trials of CUE-101, CUE-102

TipRanksNov 8 13:45 ET

Express News | Cue Biopharma Presents Positive Updated Data From Its Phase 1 Trials of Cue-101 and Cue-102 in Head and Neck Cancer and Wt1 Positive Cancers at the SITC 39TH Annual Meeting

ReutersNov 8 13:30 ET

Cue Biopharma (NASDAQ:CUE) Adds US$31m to Market Cap in the Past 7 Days, Though Investors From Three Years Ago Are Still Down 89%

Yahoo FinanceOct 8 06:13 ET